ライフサイエンスコーパス: activation syndrome

1 whom 2 eventually developed overt macrophage activation syndrome).

2 and SDF-1 and incipient signs of macrophage activation syndrome.

3 diohemodynamic involvement and no macrophage activation syndrome.

4 ey aspects of the pathogenesis of macrophage activation syndrome.

5 hagocytic lymphohistiocytosis and macrophage activation syndrome.

6 pathophysiologic features of HLS/macrophage activation syndrome.

7 thogenesis of Still's disease and macrophage activation syndrome.

8 ions, dose-limiting toxicities or macrophage activation syndrome.

9 emophagocytic lymphohistiocytosis-macrophage-activation syndrome.

10 ic mastocytosis but not monoclonal mast cell activation syndrome.

11 ning sample was diagnosed with monoclonal MC activation syndrome.

12 hagocytic lymphohistiocytosis and macrophage activation syndrome.

13 scular coagulation as features of macrophage activation syndrome.

14 tablished, and 1 patient had a monoclonal MC activation syndrome.

15 fe-threatening condition known as macrophage activation syndrome.

16 promising diagnostic markers for macrophage activation syndrome.

17 with those in patients with acute macrophage activation syndrome.

18 dentify patients with subclinical macrophage activation syndrome.

19 ssociated with the development of macrophage activation syndrome.

20 tionship between systemic JIA and macrophage activation syndrome.

21 subset in MIS-C versus FC without macrophage activation syndrome.

22 sis syndrome (HLS), also known as macrophage activation syndrome.

23 ockout (KO) mice with CpG-induced macrophage activation syndrome.

24 pathology of Still's disease and macrophage activation syndrome.

25 ic lymphohistiocytosis, including macrophage activation syndrome.

26 reactions, other inflammatory states, and MC activation syndromes.

27 in patients with mastocytosis and mast cell activation syndromes.

28 bances in cytokine signaling, and macrophage activation syndromes.

29 tension, 86; diabetes type II, 71, mast cell activation syndrome, 172; hereditary alpha tryptasemia,

30 arthritis is the association with macrophage activation syndrome, a life-threatening complication cau

31 Still's disease may also develop macrophage activation syndrome, a potentially fatal complication of

32 anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, dissem

33 ss the evaluation and treatment of mast cell activation (syndromes), allergy and anaphylaxis in mast

34 e consistent with the presence of macrophage activation syndrome and could furthermore be used as a b

35 gulation and the relation between macrophage activation syndrome and hemophagocytic lymphohistiocytos

36 e to Ifn-gamma during CpG-induced macrophage activation syndrome and is present at high levels in the

37 rstanding of the relation between macrophage activation syndrome and other clinically similar hemopha

38 ic lymphohistiocytosis, including macrophage activation syndrome, and cytokine release syndrome, all

39 immune dysregulation biomarkers, macrophage activation syndrome, and death.

40 on-gamma-driven cytokine storm in macrophage activation syndrome, and is more pronounced in critical

41 in the last decade, many areas of mast cell activation syndrome are in need of research.

42 isease includes some hallmarks of macrophage activation syndrome but is much more severe than previou

43 n sera from 7 patients with acute macrophage activation syndrome complicating systemic JIA and 16 pat

44 ha and sCD163 in diagnosing acute macrophage activation syndrome complicating systemic juvenile idiop

45 ory, and therapeutic criteria for primary MC activation syndromes described herein will provide clini

46 ic histiocytes from patients with macrophage activation syndrome display prominent mTORC1 activity.

47 ytosis and cutaneous mastocytosis, mast cell activation syndrome, eosinophilic esophagitis, eosinophi

48 Hence, sepsis patients with macrophage activation syndrome features may benefit from interleuki

49 andomized trial using features of macrophage activation syndrome for mortality risk stratification sh

50 (including those with subclinical macrophage activation syndrome) from those with normal or only mode

51 ne death was related to liso-cel (macrophage activation syndrome-haemophagocytic lymphohistiocytosis)

52 Clinically, macrophage activation syndrome has strong similarities with familia

53 thout previous therapy, including macrophage activation syndrome (hemophagocytic lymphohistiocytosis

54 ytokines that are associated with macrophage activation syndrome/hemophagocytic lymphohistiocytosis,

55 kine signature similar to that of macrophage activation syndrome/hemophagocytic lymphohistiocytosis.

56 significantly higher incidence of clonal MC activation syndrome in HalphaT(+) (10.2%) compared to Ha

57 uccessful use of cyclosporine for macrophage activation syndrome in JRA.

58 useful tool for identifying early macrophage activation syndrome in patients with systemic JIA.

59 n, pathogenesis and management of macrophage activation syndrome in systemic onset juvenile idiopathi

60 elucidate the pathophysiology of macrophage activation syndrome in systemic onset juvenile idiopathi

61 in expression may be a feature of macrophage activation syndrome in systemic-onset juvenile rheumatoi

62 ute to the increased incidence of macrophage activation syndrome in these patients.

63 sorders and is usually designated macrophage activation syndrome in those settings.

64 A total of 335 patients presenting with MC activation syndrome, including 143 insectISMs(-), 72 ISM

65 clinical features of established macrophage activation syndrome, including ferritin levels.

66 ng to the host, as is seen in the macrophage activation syndrome induced by severe infections, includ

67 Macrophage activation syndrome is a life-threatening complication s

68 Macrophage activation syndrome is characterized by an overwhelming

69 Macrophage activation syndrome is the rheumatic disease-associated

70 Dysregulated MC activation can lead to MC activation syndrome (MACS), which is observed in patient

71 agnosing and treating primary mast cell (MC) activation syndrome make use of the latest studies and c

72 e mediators hyperferritinemia and macrophage activation syndrome (MAS) and also had direct causal ass

73 linical manifestations, including macrophage activation syndrome (MAS) and lung disease (LD).

74 ssociate with disease activity in macrophage activation syndrome (MAS) and poor clinical outcomes in

75 C, and the inflammatory syndromes macrophage activation syndrome (MAS) and thrombotic microangiopathy

76 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar diseases charact

77 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are both characterized by dysr

78 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening hyperinfl

79 The deadly macrophage activation syndrome (MAS) constitutes one of the few rhe

80 HLH, using modified HLH-2004 and macrophage activation syndrome (MAS) criteria.

81 Macrophage activation syndrome (MAS) is a devastating cytokine stor

82 Macrophage activation syndrome (MAS) is an acute episode of overwhe

83 deed, the severity of CpG-induced macrophage activation syndrome (MAS) is exacerbated in IL-18BP KO m

84 The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a l

85 ytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) occur after chimeric antigen r

86 Macrophage activation syndrome (MAS), a major cause of morbidity an

87 eatening complications, including macrophage activation syndrome (MAS), a secondary form of haemophag

88 balance could be dysregulated in macrophage activation syndrome (MAS), as mirrored by the presence o

89 ory 'cytokine storm' state termed macrophage activation syndrome (MAS), culminating from a complex in

90 overexpressing mice, which have a macrophage activation syndrome (MAS)-like disease.

91 f secondary HLH (sHLH), including macrophage activation syndrome (MAS).

92 e idiopathic arthritis (SJIA) and macrophage activation syndrome (MAS).

93 tic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).

94 ytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).

95 -onset recurrent fever flares and macrophage activation syndrome (MAS).

96 orts of Kawasaki disease (KD) and macrophage activation syndrome (MAS).RESULTSTwenty-eight patients f

97 e concentrations cause symptoms in mast cell activation syndrome, mastocytosis, or anaphylaxis.

98 les from 368 adults diagnosed with mast cell activation syndrome (MCAS) and mastocytosis and determin

99 The rate of diagnosis of mast cell activation syndrome (MCAS) has increased since the disor

100 Mast cell activation syndrome (MCAS) is a term applied to several

101 -targeting drugs, the diagnosis of mast cell activation syndrome (MCAS) is appropriate.

102 Idiopathic mast cell activation syndrome (MCAS) is characterized by three dia

103 cy and prognostic impact in patients with MC activation syndrome (MCAS), cutaneous mastocytosis (CM)

104 proposed to interpret acute MCT in mast cell activation syndrome (MCAS).

105 he diagnosis and classification of mast cell activation syndromes (MCAS) and mastocytosis.

106 Primary mast cell activation syndromes (MCAS) are a group of disorders pre

107 Mastocytosis and monoclonal mast cell (MC) activation syndrome (MMAS) are heterogeneous conditions

108 c mastocytosis (SM) and monoclonal mast cell activation syndrome (MMAS), represent an increased risk

109 hagocytic lymphohistiocytosis and macrophage activation syndrome, natural killer and cytotoxic cell d

110 The macrophage activation syndrome occurred in 7 patients; infections w

111 om showed evidence of subclinical macrophage activation syndrome (of whom 2 eventually developed over

112 nal mast cell disorder (monoclonal mast cell activation syndrome or systemic mastocytosis) and thus c

113 n disorders (inflammasomopathies), NF-kappaB activation syndromes, protein misfolding disorders, comp

114 and excess interleukin-18 (IL-18; macrophage activation syndrome) provide clues.

115 Mast cell activation syndrome refers to a group of disorders with

116 these 5 patients developed overt macrophage activation syndrome several months later.

117 emophagocytic lymphohistiocytosis/macrophage activation syndrome, severe malarial anemia during Plasm

118 ty-eight patients (17%) developed macrophage-activation syndrome, sometimes related to acute Epstein-

119 ersistent, or relapsing secondary macrophage activation syndrome, the addition of prompt individualiz

120 sIL-2Ralpha in the patients with macrophage activation syndrome was 19,646 pg/ml (interquartile rang

121 level of sCD163 in patients with macrophage activation syndrome was 23,000 ng/ml (IQR 14,191), compa

122 Mast cell activation syndrome was confirmed in only 2% of patients

123 h as systemic mastocytosis and monoclonal MC activation syndrome were negative.

124 cell-associated neurotoxicity or macrophage activation syndromes were reported.

125 herISMs(-)), 56 ISMs(+), and 64 nonclonal MC activation syndrome, were studied.

126 s may suggest a relationship with macrophage activation syndrome, while type 1 DC upregulation implie

127 In patients with macrophage activation syndrome, whose disease does not sufficiently

128 A monoclonal mast cell activation syndrome with aberrant mast cells (MC) at ext

129 g both inflammatory arthritis and macrophage activation syndrome with hemophagocytosis, a cellular ma